

CONTENTS

Vol. 39 No. 4 July 2008

Japanese Journal of Clinical Pharmacology
and Therapeutics

[Memorial] YUTAKA MIZUSHIMA, MD, PhD	Shinichi KAWAI	109
Forum		
A Manual to Facilitate Clinical Data Collection from the Doctors in Other Hospitals Whom Subjects Consult for Serious Adverse Events during Clinical Trials	Naoko YAMADA, et al.	111
Proposals for the Solution of the Drug-Lag Problem in Japan through the Promotion of Clinical Pharmacological Science	Tadao SUZUKI	117
Report		
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 2	Yasunori SATO	123
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1	Tsuyoshi FUKUDA	127
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1	Takeko OISHI	131
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1	Toshihiro TANAKA	135
Proceedings of the 28th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics		
Contents		71S
Symposium 6 “Training for Sohyaku/Ikuyaku Medical Staff and Team”		73S
Symposium 9 “PK/PD Guidance for Antimicrobials —Future Trend for the Clinical Trial of Antimicrobials—”		85S
Symposium 10 “Cancer Pharmacotherapy in the New Era of Pharmacogenomics”		95S
Symposium 11 “What Lesson Should We Learn from the TGN1412 Case ?”		107S
Twilight Seminar for Clinical Research Coordinator (CRC)		
Part 1 “Continuing Education for CRCs, Corresponding to the Expansion of Their Roles”		117S
Part 2 “Education and Training for CRC : Beginner's Course and Advanced Course”		129S
Information for Authors		123E
Announcements		125E

Proceedings of the 28th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

November 28–December 1, 2007 (Utsunomiya)

President : Akio FUJIMURA (Jichi Medical University)

Symposium 1 “Systems for Promoting Registration Trials with Global Competitiveness”

Summary	Shigeru KAGEYAMA, Hiroshi WATANABE	15S
S1-1 From Investigator in Clinical Pharmacological Study	Kazuo UMEMURA	17S
S1-2 Construction of the Active Execution Groups for Clinical Trials Expands the Scale and Improves Execution Speed	Takashi MORITOYO, et al.	19S
S1-3 For the Quality Control of Clinical Trials and the Protection of Subjects	Hajime IJIMA	21S
S1-4 Talent Development to Promote Drug Development with Globally Competitive Performance	Kihito TAKAHASHI	23S
S1-5 Infrastructure Building to Do Clinical Research in a “Core” Hospital	Haruko YAMAMOTO	25S

Symposium 2 “Regarding Publication by MHLW of Manuals for Management of Individual Serious Adverse Drug Reactions”

S2-1 The Manuals for Interstitial Pneumonia, Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) and NSAIDs-induced Asthma (Aspirin Asthma)	Keishi KUBO	27S
S2-2 Basis of Drug-induced Lung Injury in Japan	Arata AZUMA	29S
S2-3 Review on Drug-induced Lung Injury	Shu HASHIMOTO, et al.	31S
S2-4 Statins and Rhabdomyolysis	Haruo NAKAMURA	33S
S2-5 Need for Setting Diagnostic Criteria of Rhabdomyolysis	Kazuhiro HARADA	35S

Symposium 3 “Scientific Issues Required for Manufacturing and Nurturing Generic Drugs”

Summary	Kitaro OKA, Hiroshi YAMADA	37S
S3-1 Sciences for the Evaluation of Clinical Efficacy and Safety of Generic Medicines : From the View Point of Biopharmaceutics	Hiroyasu OGATA	39S
S3-2 Safety of Generic Drugs from Clinical Point of View	Kazuhiro HARADA	41S
S3-3 Several Issues of Promoting the Use of Generic Drugs in Japan : A Matter of Package Inserts	Eiji UCHIDA	43S
S3-4 Post-Marketing Studies and Product Evolution of Generic Drugs	Yasufumi SAWADA	45S
S3-5 “Genetic Drug”~It’s Benefit and risk~	Mikio MASADA	47S

Symposium 4 “Lifecycle Management of Drugs”

Summary	Junko SATO, Hajime YASUHARA	49S
S4-1 Ikuyaku : Drug Fostering and Evolution	Shigeyuki NAKANO	51S
S4-2 Life Cycle Management of Antihypercholesterolemia Agent	Masaharu HANAWA	53S
S4-3 Lifecycle Management of Medical Products in the Pharmaceutical Company	Masahiko KIKUCHI	55S
S4-4 The Future Perspective and Effort of PMDA	Kazuhiko MORI	57S

Symposium 5 “Significance of Japanese Mega-Studies of Drug for Cardiovascular Disease”

Summary	Junichi HASEGAWA, Hiroshi KISHIDA	59S
S5-1 EBM Research in the Cardiovascular Fields : Issues of Clinical Trials from the View Point of JAMP Study	Kenji UESHIMA, et al.	61S
S5-2 Experience with J-Rhythm Study : A Mega-Study of Atrial Fibrillation	Takeshi YAMASHITA	63S
S5-3 Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure (J-CHF)	Junichi AZUMA, et al.	65S
S5-4 JIKEI HEART Study	Michihiro YOSHIMURA, et al.	67S
S5-5 Primary Prevention of Cardiovascular Disease with Pravastatin in Japan (MEGA Study)	Kyoichi MIZUNO, et al.	69S

Proceedings of the 28th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

November 28–December 1, 2007 (Utsunomiya)

President: Akio FUJIMURA (Jichi Medical University)

Symposium 6 “Training for Sohyaku/ Ikuyaku Medical Staff and Team”

Summary	Shigeyuki NAKANO, Akira KAMIYA	73S
S6-1 New Essential Concept of “Sohyaku/ Ikuyaku Medical Team and Staff” for Development and Fostering of Useful Drugs	Shigeyuki NAKANO	75S
S6-2 Postgraduate Education and Training of the Medical Staff Engaged in Pharmaceutical Medicine	Hiroshi YAMADA	77S
S6-3 Educational Activities for Clinical Trial to Clinical Staff in University Hospital	Toshiko ISHIBASHI	79S
S6-4 Encouragement of the Research Staff and Team; Experience of Hospitals, Research Institutes and a Pharmaceutical Company	Miyuki NIIMI	81S
S6-5 Expectation of Well-Trained Clinical Research Team	Akira KAMIYA	83S

Symposium 9 “PK/PD Guidance for Antimicrobials—Future Trend for the Clinical Trial of Antimicrobials—”

S9-1 Outline of PK/PD Guidance in Japanese Society of Chemotherapy	Seiji HORI	85S
S9-2 PK/PD Guidance for Antimicrobial Agents: From the View Point of Regulators	Junko SATO	87S
S9-3 Clinical Studies of Antimicrobial Agents from Now on—Industrial Perspective—	Masaki HIRAOKA	89S
S9-4 PK/PD Guidance for Antimicrobial Agents—Directions for Clinical Trials of Antimicrobial Agents in Children—	Satoshi IWATA	91S
S9-5 Future Trends on PK-PD and Clinical Studies of Antibiotics	Takashi NOGUCHI	93S

Symposium 10 “Cancer Pharmacotherapy in the New Era of Pharmacogenomics”

Summary	Takanori UEDA, Yasutsuna SASAKI	95S
S10-1 Personalized Medicine by Biomarker	Kazuto NISHIO	97S
S10-2 Pharmacogenetics in Childhood Acute Lymphoblastic Leukemia Therapy	Shinji KISHI, et al.	99S
S10-3 Proteasome Inhibitor, Bortezomib, for the Treatment of Myeloma and Lymphoma: Reconsiderations on the Administrations Based on its Pharmacokinetic Profiles	Kensei TOBINAI	101S
S10-4 Pharmacogenomic Factors Influencing the 5-Fluorouracil Prodrug Tegafur	Kazuhiro ARAKI, et al.	103S
S10-5 Molecular Targeting Drug for GI Malignancy	Toshihiko DOI	105S

Symposium 11 “What Lesson should We Learn from the TGN1412 Case ?”

S11-1 The Impact on NDA Review and Clinical Trials Consultation Service of PMDA	Kazuhiko MORI	107S
S11-2 Proposal from Toxicologist on the TGN1412 Accident	Kazuhiko MATSUMOTO	109S
S11-3 Considering as a Clinical Pharmacologist; How Introduce the Recommendation from ESG of MHRA to Japan	Naoki UCHIDA	111S
S11-4 Ethical, Regulatory Issues to Learn from the TGN1412 Case	Chieko KURIHARA	113S
S11-5 What have We Learned from TGN1412 Incidence ?; A Viewpoint from Industry	Masaru IWASAKI, et al.	115S

Twilight Seminar for Clinical Research Coordinator (CRC)

Part 1 “Continuing Education for CRCs, Corresponding to the Expansion of Their Roles”

TW1-1 About Continued Education Required for the Career Improvement of CRC in the Position of SMO	Eri IKEDA	117S
TW1-2 Medical Moral Education by CRC	Junko ISHIZAKI	119S
TW1-3 Continuous Education for CRCs to Prepare International Clinical Trials	Eriko AOTANI	121S
TW1-4 CRC Management Skill Enhancement	Hideyuki IKEMATSU	123S
TW1-5 The Continuing Education to the Clinical Trial Profession—The Activity SoCRA Japan Chapter—	Hisae EGUCHI	125S
TW1-6 What I Learned from My Career Change: From a Hospital to a Pharmaceutical Company	Rie YONEYAMA	127S

Part 2 “Education and Training for CRC: Beginner’s Course and Advanced Course”

JSCPT Board Certified CRC and Education System in Japan	Shigeyuki NAKANO	129S
---	------------------	------